Cases & Deals

Share

Benitec Biopharma redomiciled to U.S.

April 2020

Client(s) Benitec Biopharma Inc. and Benitec Biopharma Limited

Jones Day advised Benitec Biopharma Limited (ASX and NASDAQ listed) ("Benitec Australia") in its redomiciliation from Australia to the U.S. pursuant to a statutory scheme of arrangement under Australian law (the "Scheme"). Upon the completion of the Scheme, all of Benitec Australia's outstanding ordinary shares were exchanged for newly issued shares of common stock of Benitec Biopharma Inc., a Delaware corporation newly incorporated for the Scheme ("Benitec Delaware"); Benitec Australia and its subsidiaries became wholly owned subsidiaries of Benitec Delaware; and Benitec Delaware became the successor of Benitec Australia and its common stock commenced trading on Nasdaq under the symbol "BNTC".

Throughout the redomiciliation process, Jones Day advised Benitec Australia and Benitec Delaware on matters related to the Scheme, corporate governance, listing application, disclosure requirements, tax, and employee benefit-related matters from both U.S. and Australian perspectives.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.